Oncology Flashcards
Indication for masectomy
Indication for chest wall radiation after masectomy
Indication for adjuvant therapy for breast cancer
Should new breast cancer mets be biopsied?
Small Cell Lung Cancer characteristics
Gastric Cancer Treatment
Hereditary nonpolyposis colon cancer diagnostic criteria
Colon cancer treatment
Follow-up for colon cancer
treatment of anal cancer
HCC treatment
Treatment of Neuroendocrine tumors
Ovarian Cancer Testing
Ovarian Cancer Treatment
Treatment of endometrial cancers
Treatment of Prostate Cancer
Testicular Cancer Testing
Testicular Cancer Treatment
RCC related disease
Treatment of RCC
Types of Thyroid Cancer
Treatment of thyroid cancer
Indolent Lymphoma
Agrressive Lymphoma
Hodgkins Lymphoma Treatment
Treatment of Neutropenic Fevers
High-risk prostate cancer
prostate-specific antigen (PSA) level greater than 20 ng/mL (20 µg/L), a Gleason score of 8 to 10, or evidence of extraprostatic extension of the cancer.
advanced-stage follicular lymphoma treatment
rituximab plus chemotherapy leads to remission in more than 90% of patients, although the disease will recur in most patients.
aggressive B-cell lymphomas types
diffuse large B-cell and Burkitt lymphoma
aggressive B-cell lymphomas treatment
Standard therapy for most patients with advanced-stage diffuse large B-cell lymphoma is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Hodgkin lymphoma diagnosis
established with a lymph node biopsy specimen showing Reed-Sternberg cells
Hodgkin lymphoma treatment
All patients with classic Hodgkin lymphoma, regardless of stage, receive chemotherapy(doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)).
Patients with early-stage nodular lymphocyte–predominant Hodgkin lymphoma may be treated with radiation alone, but in the more advanced stages, they should be treated with rituximab with or without chemotherapy.
Complete response indicated by PET scan after two to three cycles of chemotherapy can allow some patients with early-stage classical Hodgkin lymphoma to forgo radiation therapy.
Toxicities:
Fluoropyrimidines (5-fluorouracil and capecitabine)
Epidermal growth factor receptor (EGFR) inhibitors (erlotinib and gefitinib):
Monoclonal antibodies against EGFR (cetuximab and panitumumab):
Trastuzumab:
Bleomycin:
Gemcitabine:
Cisplatin:
Bevacizumab:
Toxicities:
Fluoropyrimidines (5-fluorouracil and capecitabine): palmar-plantar erythrodysesthesia (“hand-foot syndrome”), coronary vasospasm, cerebellar toxicity
Epidermal growth factor receptor (EGFR) inhibitors (erlotinib and gefitinib): pustular acneiform eruptions, pulmonary toxicity
Monoclonal antibodies against EGFR (cetuximab and panitumumab): pustular acneiform eruptions, pulmonary toxicity
Trastuzumab: pulmonary toxicity
Bleomycin: pulmonary toxicity
Gemcitabine: Hemolytic uremic syndrome
Cisplatin: acute tubular necrosis, Peripheral neuropathy
Bevacizumab: hypertension, reversible posterior encephalopathy syndrome
pembrolizumab and nivolumab (anti–programmed death receptor-1 [PD-1]): colitis, pneumonitis, hepatitis, dermatitis, hypophysitis, thyroiditis, and adrenalitis.
